Prepared by reacting BSA with glycoaldehyde under sterile conditions. Glycated-BSA shows a 5,000 - 10,000% increase in fluorescence as compared to normal BSA (confirmed by fluorescence spectrophotometry, excitation/emission 370/440 nm). AGE-BSA has been reported to induce apoptosis in cultured human umbilical vein endothelial cells and inhibit nitric oxide synthase activity in proximal tubular epithelial cells. Advanced glycation end products and their receptors have been implicated in the pathogenesis of diabetes, induction of proinflammatory cytokines, and stimulation of smooth muscle proliferation, and fibronectin production.

Prepared by reacting bovine serum albumin (BSA) with glycoaldehyde under sterile conditions. Fluorescence of AGE-BSA is confirmed by fluorescence spectrophotometry, excitation/emission = 370/440 nm. Glycated BSA shows a 5000-10,000% increase in fluorescence compared to control BSA. AGE and their receptors have been implicated in the pathogenesis of diabetes, induction of pro-inflammatory cytokines, and stimulation of smooth muscle proliferation and fibronectin production. AGE-BSA has also been shown to induce apoptosis in cultured human umbilical vein endothelial cells (HUVEC) and inhibit nitric oxide synthase activity in proximal tubular epithelial cells of the kidney.

In sterile-filtered PBS.

Okamoto, T., et al. 2002. Microvasc. Res.63, 186.
Ohgami, N., et al. 2001. J. Biol. Chem.276, 3195.
Wang, R., et al. 2001. J. Nippon Med. Sch.68, 472.
Sakata, N., et al. 2000. J. Atheroscler. Thromb.7, 169.
Verbeke, P., et al. 2000. Biochim. Biophys. Acta1502, 481.
Farboud, B., et al. 1999. Mol. Vis.5, 11.
Huang, J.-S., et al. 1999. Biochem. J.342, 231.
Min, C., et al. 1999. Diabetes Res. Clin. Pract.46, 197.
Neumann, A., et al. 1999. FEBS Lett.453, 283.
Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun.256, 549.
Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol.20, 83.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)